Drs. Raaschou and Simard contributed equally to this work.
Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents†
Version of Record online: 29 JUN 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 63, Issue 7, pages 1812–1822, July 2011
How to Cite
Raaschou, P., Simard, J. F., Neovius, M., Askling, J. and Anti-Rheumatic Therapy in Sweden Study Group (2011), Does cancer that occurs during or after anti–tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis & Rheumatism, 63: 1812–1822. doi: 10.1002/art.30247
Members of the Anti-Rheumatic Therapy in Sweden Study Group are listed in Appendix A.
- Issue online: 29 JUN 2011
- Version of Record online: 29 JUN 2011
- Accepted manuscript online: 18 JAN 2011 12:08PM EST
- Manuscript Accepted: 6 JAN 2011
- Manuscript Received: 14 APR 2010
- Swedish Research Council
- Swedish Cancer Society
- Stockholm County Council
- Abbott Immunology
- Bristol-Myers Squibb
- King Gustav V
- Kock Foundations
- Medical Faculty of Lund University
- Swedish National Board of Health and Welfare
- 9International Classification of Diseases, seventh revision. Geneva: World Health Organization; 1955.
- 17TNM classifications of malignant tumors. 6th ed. New York: Wiley-Liss; 2002., .